<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">JCO Precis Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">JCO Precis Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>JCO precision oncology</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2473-4284</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC12088707</article-id>
        <article-id pub-id-type="pmcid-ver">PMC12088707.1</article-id>
        <article-id pub-id-type="pmcaid">12088707</article-id>
        <article-id pub-id-type="pmcaiid">12088707</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS2022638</article-id>
        <article-id pub-id-type="pmid">39499893</article-id>
        <article-id pub-id-type="doi">10.1200/PO.24.00287</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS2022638</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA2022638</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iyer</surname>
              <given-names initials="G">Gopa</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tangen</surname>
              <given-names initials="CM">Catherine M.</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sarfaty</surname>
              <given-names initials="M">Michal</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Regazzi</surname>
              <given-names initials="AM">Ashley M.</given-names>
            </name>
            <degrees>BS</degrees>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="IL">I-Ling</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Fong</surname>
              <given-names initials="M">Megan</given-names>
            </name>
            <degrees>BS</degrees>
            <xref rid="A6" ref-type="aff">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Choi</surname>
              <given-names initials="W">Woonyoung</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="A6" ref-type="aff">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dinney</surname>
              <given-names initials="CPN">Colin P.N.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Flaig</surname>
              <given-names initials="TW">Thomas W.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="A7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Thompson</surname>
              <given-names initials="IM">Ian M.</given-names>
              <suffix>Jr</suffix>
            </name>
            <degrees>MD</degrees>
            <xref rid="A8" ref-type="aff">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lerner</surname>
              <given-names initials="SP">Seth P.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="A9" ref-type="aff">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>McConkey</surname>
              <given-names initials="DJ">David J.</given-names>
            </name>
            <degrees>PhD</degrees>
            <xref rid="A6" ref-type="aff">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rosenberg</surname>
              <given-names initials="JE">Jonathan E.</given-names>
            </name>
            <degrees>MD</degrees>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A2" ref-type="aff">2</xref>
            <xref rid="CR1" ref-type="corresp">*</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A2"><label>2</label>Weill Cornell Medical College, New York, NY</aff>
        <aff id="A3"><label>3</label>Fred Hutchinson Cancer Research Center, Seattle, WA</aff>
        <aff id="A4"><label>4</label>Rabin Medical Center, Israel</aff>
        <aff id="A5"><label>5</label>University of Texas MD Anderson Cancer Center, Houston, TX</aff>
        <aff id="A6"><label>6</label>Johns Hopkins School of Medicine, Baltimore, MD</aff>
        <aff id="A7"><label>7</label>University of Colorado, School of Medicine, Aurora, CO</aff>
        <aff id="A8"><label>8</label>CHRISTUS Medical Center Hospital, UT Health Science Center, San Antonio, TX</aff>
        <aff id="A9"><label>9</label>Baylor College of Medicine, Houston, TX 77030</aff>
        <author-notes>
          <corresp id="CR1"><label>*</label>Corresponding author: Jonathan E. Rosenberg, MD, 353 E. 68<sup>th</sup> Street, New York, NY 10065, <email>rosenbj1@mskcc.org</email></corresp>
        </author-notes>
        <pub-date pub-type="ppub">
          <month>11</month>
          <year>2024</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>05</day>
          <month>11</month>
          <year>2024</year>
        </pub-date>
        <volume>8</volume>
        <issue-id pub-id-type="pmc-issue-id">488777</issue-id>
        <fpage>e2400287</fpage>
        <lpage>e2400287</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>20</day>
              <month>04</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>05</day>
              <month>11</month>
              <year>2025</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-05-20 16:25:22.483">
              <day>20</day>
              <month>05</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2022638.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose:</title>
            <p id="P1">Alterations in DNA damage response (DDR) genes, including <italic toggle="yes">ERCC2</italic>, have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314 (S1314) trial enrolled patients with MIBC who received one of two NAC regimens followed by radical cystectomy. We examined the prevalence of DDR alterations in NAC responders versus non-responders and correlated DDR alteration status with response.</p>
          </sec>
          <sec id="S2">
            <title>Methods:</title>
            <p id="P2">Pre-treatment tumor specimens from 179 evaluable patients underwent Next Generation Sequencing (MSK-IMPACT assay). Associations were determined between any or only deleterious alterations within nine pre-defined DDR genes, or any alterations in <italic toggle="yes">ERCC2</italic>, and progression-free and overall survival using Cox regression, and, in a subset of evaluable patients, pathologic response (complete response, pT0, or down-staging to &lt;pT2) using logistic regression, adjusting for clinical stage and performance status.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P3">Deleterious DDR alterations were detected in 41/179 patients (23%). Of 151 patients evaluable for pathologic response, patients with deleterious DDR alterations (n=39) demonstrated a higher pathologic response rate than those without (odds ratio [OR] 3.24; 95% CI 1.51, 6.94, p=0.003). In 24 ERCC2-mutant patients, the OR for pT0 was 3.33 (95% CI 1.35, 8.22, p=0.009) and 2.33 for &lt;pT2 (95% CI 0.92, 5.89, p=0.073). The association between deleterious DDR alterations and PFS provided an estimate of HR 0.54 (95% CI 0.29, 1.01, p=0.053).</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P4">Deleterious DDR alterations were associated with pathologic response following NAC in S1314. Functional validation of ERCC2 and other DDR alterations is underway to help refine such alterations as biomarkers of NAC in patients with bladder cancer.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>DNA damage response</kwd>
          <kwd>urothelial carcinoma</kwd>
          <kwd>SWOG1314</kwd>
          <kwd>bladder cancer</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-exception-type</meta-name>
            <meta-value>EMBARGO</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>4</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
